Effects of intravenous sotalol in patients with atrioventricular accessory pathways

Touboul, P; Atallah, G; Kirkorian, Gilbert; Lavaud, Pierre; Mathieu, M.; Dellinger, A.

doi:10.1016/0002-8703(87)90751-4

Cited by 24 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of IV sotalol to treat PSVT due to AVNRT and AVRT is supported by 2 trials of excellent quality (LOE 1) 144,145 and data extrapolated from 1 study (LOE 7) demonstrating its slowing effects on accessory pathway conduction. 146 No data related to the use of parenteral bretylium, ibutilide, or IV disopyramide (NAUS) for treat-maneuvers are variable and depend on the presence of underlying conditions, the patient's level of cooperation, and the patient's age. Ice water applied to the face is most effective in infants and young children.…”

Section: N E W S C I E N C Ementioning

confidence: 99%

Treatment of tachyarrhythmias

Atkins

Dorian

Gonzalez

et al. 2001

Annals of Emergency Medicine

View full text Add to dashboard Cite

Section: N E W S C I E N C Ementioning

confidence: 99%

Treatment of tachyarrhythmias

Atkins

Dorian

Gonzalez

et al. 2001

Annals of Emergency Medicine

View full text Add to dashboard Cite

“…Otherwise, when Wolff-Parkinson-White syndrome is known or suspected, cardiology consultation is indicated for the selection of the most appropriate management strategy. Antiarrhythmic agents that have direct effects on accessory pathway conduction and refractoriness (such as procainamide, propafenone, 127 flecainide, 127,161 or amiodarone) are more likely to slow ventricular response during preexcited AF or atrial flutter as well as convert the arrhythmia to sinus rhythm.…”

Section: Atrial Fibrillation/fluttermentioning

confidence: 99%

Part 6: Advanced Cardiovascular Life Support : Section 5: Pharmacology I: Agents for Arrhythmias

2000

Circulation

View full text Add to dashboard Cite

“…Hierzu gehört die Verlängerung der effektiven und absoluten Refraktärzeit sowohl im Vorhof-und Ventrikelmyokard als auch im Erregungsleitungssystem (7,39). Die Wirksamkeit in der Unterdrückung von Vorhofflimmern wird dabei vor allem der Wirkung am Vorhofmyokard zugeschrieben (18).…”

Section: Patientenkollektiv/statistikunclassified

Die medikamentöse Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/-flattern

Patten¹,

Sonntag²,

Lüderitz³

et al. 1999

Zeitschrift f�r Kardiologie

View full text Add to dashboard Cite

The indication to treat symptomatic paroxysmal atrial fibrillation is discussed controversely. Successful medical treatment may result in the reduction of symptoms by improving hemodynamics in a reduction of thromboembolic events. However, several antiarrhythmic drugs are also known to increase the risk of proarrhythmic events. A randomized, double-blind, and placebo-controlled multicenter trial with 1000 patients to be recruited was designed to compare the effects of two antiarrhythmic drugs frequently used in Germany for the treatment of atrial fibrillation, Sotalol and the fixed combination of chinidin and verapamil (Cordichin). Patients with symptomatic paroxysmal atrial fibrillation/atrial flutter will be observed for a period of one year. The occurrence of paroxysmal atrial fibrillation is documented by transtelephonic ECG monitoring. Patients with document an ECG once daily, and recording is mandatory in case of symptoms. ECGs are transmitted to a central data base for analysis. This clinical trial is designed to answer the following questions: (1) What is the average rate of spontaneous events of symptomatic atrial fibrillation? (2) Is it possible to reduce the frequency of symptomatic events by chronic antiarrhythmic drug administration? (3) What is the long-term frequency for the occurrence of severe side-effects under antiarrhythmic medication? The primary endpoint is defined as the time to first recurrence of symptomatic arrhythmia after reaching steady-state plasma concentrations of the study medication. The trial started in November 1997 and is planned to be finished by the end of 1999.

show abstract

Effects of intravenous sotalol in patients with atrioventricular accessory pathways

Cited by 24 publications

References 20 publications

Treatment of tachyarrhythmias

Treatment of tachyarrhythmias

Part 6: Advanced Cardiovascular Life Support : Section 5: Pharmacology I: Agents for Arrhythmias

Die medikamentöse Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/-flattern

Contact Info

Product

Resources

About